<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="72035">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01709942</url>
  </required_header>
  <id_info>
    <org_study_id>C05</org_study_id>
    <nct_id>NCT01709942</nct_id>
  </id_info>
  <brief_title>Use of Degarelix in Controlled Ovarian Hyperstimulation (COH) Protocol for Women With PoliCystic Ovarian Syndrome (PCOS)</brief_title>
  <official_title>Use of Long Acting GnRH Antagonist to Prevent Ovarian HyperStimulation Syndrome (OHSS) in PCOS Women Undergoing COH for IVF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre for Endocrinology and Reproductive Medicine, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre for Endocrinology and Reproductive Medicine, Italy</source>
  <oversight_info>
    <authority>Italy: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the effectiveness of degarelix, a long acting GnRH antagonist administered in
      a unique administration of 20 mg the first day of menstrual cycle, to prevent ovarian
      hyperstimulation syndrome (OHSS) in PCOS women at risk to develop OHSS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women with PCOS are at risk to develop OHSS when stimulated with gonadotrophins for IVF. For
      this reason in this study the degarelix was tested in order to minimize the risk of OHSS as
      well as to improve the pregnancy rate in these patients. The use of long acting GnRH
      antagonist promotes a deep suppression of LH and consequently the activity of theca cells,
      which secrete androgens (the precursors of estradiol), and consequently the levels of
      estradiol remains low. Comparing the long acting GnRH antagonist at the first day of cycle
      with a flexible GnRH antagonist protocol in a group of patients with PCOS will be useful in
      order to establish the best way to perform controlled hyperstimulation in IVF cycles and
      minimize the risk of OHSS.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>PREGNANCY RATE</measure>
    <time_frame>6 MONTHS</time_frame>
    <safety_issue>No</safety_issue>
    <description>number of ongoing pregnancy obtained in the group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ovarian hyperstimulation syndrome rate</measure>
    <time_frame>6 MONTHS</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>incidence of ovarian hyperstimulation syndrome in the groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>implantation rate</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>number of implanted embryos divided for the number of transferred embryos</description>
  </secondary_outcome>
  <other_outcome>
    <measure>number of mature oocytes</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>number of mature oocytes obtained in each patient</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>PCOS</condition>
  <condition>OHSS</condition>
  <condition>INFERTILITY</condition>
  <arm_group>
    <arm_group_label>degarelix group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>group of patients treated with long acting GnRH antagonist</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cetrorelix 0.25mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients treated with gonadotropin and Cetrorelix ina flexible GnRH antagonist protocol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>degarelix (long acting GnRH antagonist)</intervention_name>
    <description>20 mg of degarelix the first day of menstrual cycle before starting with gonadotrophins administration</description>
    <arm_group_label>degarelix group</arm_group_label>
    <other_name>Firmagon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cetrorelix  0.25mg</intervention_name>
    <description>0.25mg of cetrorelix during treatment with gonadotrophins when estradiol levels were &gt;300pg/ml</description>
    <arm_group_label>Cetrorelix 0.25mg</arm_group_label>
    <other_name>cetrotide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women with PCOS

          -  previous OHSS

          -  Infertility

        Exclusion Criteria:

          -  more than 38 years old

          -  Body mass index pore than 30

          -  other systemic diseases
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Sbracia, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre for Endocrinology and Reproductive Medicine, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cerm-Hungaria</name>
      <address>
        <city>Rome</city>
        <zip>00153</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Sbracia, MD</last_name>
      <phone>+393479037433</phone>
      <email>marcandrea@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Fabio Scarpellini, MD</last_name>
      <phone>+393278779064</phone>
      <email>quelidebercia@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Marco Sbracia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabio Scarpellini, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>García-Velasco JA, Kupesic S, Pellicer A, Bourgain C, Simón C, Mrazek M, Devroey P, Arce JC. Follicular and endocrine profiles associated with different GnRH-antagonist regimens: a randomized controlled trial. Reprod Biomed Online. 2012 Feb;24(2):153-62. doi: 10.1016/j.rbmo.2011.10.016. Epub 2011 Nov 4.</citation>
    <PMID>22197127</PMID>
  </results_reference>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 2, 2013</lastchanged_date>
  <firstreceived_date>October 17, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre for Endocrinology and Reproductive Medicine, Italy</investigator_affiliation>
    <investigator_full_name>Fabio Scarpellini</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>GnRH antagonist</keyword>
  <keyword>PCOS</keyword>
  <keyword>OHSS</keyword>
  <keyword>COH</keyword>
  <keyword>IVF</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Ovarian Hyperstimulation Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cetrorelix</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
